Approval · Notice of Compliance 29261 · 2022
COVERSYL PLUS: Notice of Compliance 29261
Issued October 21, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29261
- Date
- October 21, 2022
- Company
- Servier Canada Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety Update to the Product Monograph (PM) and to convert the PM to the 2020 Master Template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COVERSYL PLUS | Not yet assigned | — |
| COVERSYL PLUS HD | Not yet assigned | — |
| COVERSYL PLUS LD | Not yet assigned | — |
Medicinal ingredients
- PERINDOPRIL ERBUMINE 4 MG per TAB
- INDAPAMIDE 1.25 MG per TAB
- PERINDOPRIL ERBUMINE 8 MG per TAB
- INDAPAMIDE 2.5 MG per TAB
- PERINDOPRIL ERBUMINE 2 MG per TAB
- INDAPAMIDE 0.625 MG per TAB